Abstract
The creation of a fundamentally new class of medicines aimed at inhibiting IL-17A, one of the main pro-inflammatory cytokines in the development of psoriasis and psoriatic arthritis, opens up broad prospects for patients to receive effective and safe pathogenetic psoriasis therapy due to the precise anti-inflammatory target. The selective blockade of IL-17A makes it possible to block the same name of receptor binding, regardless of the route of its synthesis, unlike other groups of biologics, such as i-TNFα and i-IL12/23. After a fundamentally new selective product, secukinumab (blocker IL-17A) appeared on the Russian market, it became possible to provide patients with psoriasis with fast and effective therapy, and for patients to receive a fundamentally new quality of life within a few weeks after the start of therapy. In addition, secukinumab provide good tolerability and favorable safety for comorbidities. The article presents clinical cases patients with psoriasis and psoriatic arthritis treating by secukinumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
